fluticasone furoate/umeclidinium/vilanterol vs fluticasone propionate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

fluticasone propionate

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT07664527 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolfluticasone propionate
Severe exacerbations, annualised rate—Trial running · NCT046517771.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
1 other result
  • 2.6 vs 2.7 250/50 mcg BID · wk 52 · n 310 · Phase 4 · secondary NCT00452348
Trough FEV1, change0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
0.2 vs 0.1+0.2 vs placebo100 mcg · wk 12 · n 129NCT02139644
25 other results
  • 0.2 vs 0.1 50 mcg · wk 12 · n 128 · Phase 3 · primary NCT02139644
  • 0.1 vs 0.0 200 mcg · wk 26 · n 120 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · primary NCT01576718
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · primary NCT01576718
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · secondary NCT01576718
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · secondary NCT01576718
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767
ACQ-5, change—Trial running · NCT04651777—Not posted · NCT00158834
OCS dose reduction—Trial running · NCT04651777—Not posted · NCT00158834

Severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
fluticasone propionate
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
1 other result
  • 2.6 vs 2.7 250/50 mcg BID · wk 52 · n 310 · Phase 4 · secondary NCT00452348

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
fluticasone propionate
0.2 vs 0.1+0.2 vs placebo100 mcg · wk 12 · n 129NCT02139644
25 other results
  • 0.2 vs 0.1 50 mcg · wk 12 · n 128 · Phase 3 · primary NCT02139644
  • 0.1 vs 0.0 200 mcg · wk 26 · n 120 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · primary NCT01576718
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · primary NCT01576718
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · secondary NCT01576718
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · secondary NCT01576718
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767

ACQ-5, change

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
fluticasone propionate
—Not posted · NCT00158834

OCS dose reduction

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
fluticasone propionate
—Not posted · NCT00158834
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · fluticasone propionate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterolfluticasone propionate
Dropout rate
7.7%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
—100/25 µg QDb
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
53.1%Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
37.5%Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
26.5%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
25.5%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
2.8%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
28%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
27.5%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
20.3%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
21.1%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.4%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.4%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.7%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
—100/25 µg QDb
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
—Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
3.3%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
1.9%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
—50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
1.7%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.8%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.9%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Serious AEs
4.4%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.4%100/25 µg QDb
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
0%50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
0%Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
4.6%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
2.3%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
2%50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
0%100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
1.9%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0.8%100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
0%50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
9.8%200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
6.4%200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5%100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5.5%100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
0.6%100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
0.8%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.8%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
—25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0.9%100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0.9%50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0%400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
1.9%100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
1%50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100/31.25/25 mcga
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination
100/25 µg QDb
upper respiratory tract infection 6.8%
NCT02730351 · Phase 4 · registry result, not featured evidence
show 29 more results
250/50 mcg BID
upper respiratory tract infection 20.3%
headache 18.3%
nasopharyngitis 17.6%
NCT00452699 · Phase 4 · registry result, not featured evidence
250/50 mcg BID
nasopharyngitis 17.4%
headache 16.5%
upper respiratory tract infection 14.5%
NCT00452348 · Phase 4 · registry result, not featured evidence
50/100 mcg BD
headache 18%
nasopharyngitis 9.3%
rhinitis 8%
NCT00353873 · Phase 4 · registry result, not featured evidence
100/50mcg BID
headache 3.2%
upper respiratory tract infection 3.2%
abdominal pain upper 2.4%
NCT00118716 · Phase 4 · registry result, not featured evidence
50/12.5 mcg BID
nasopharyngitis 4.3% (placebo 5.3%)
NCT02980133 · Phase 3 · registry result, not featured evidence
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
100 mcg
headache 7% (placebo 3.9%)
nasopharyngitis 7% (placebo 3.1%)
upper respiratory tract infection 3.1% (placebo 4.7%)
NCT02139644 · Phase 3 · registry result, not featured evidence
50 mcg
nasopharyngitis 5.4% (placebo 3.1%)
upper respiratory tract infection 5.4% (placebo 4.7%)
headache 1.6% (placebo 3.9%)
NCT02139644 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
200/12.5 mcg
upper respiratory tract infection 18%
sinusitis 10.5%
nasopharyngitis 9%
NCT02175771 · Phase 3 · registry result, not featured evidence
200 mcg
upper respiratory tract infection 13.6%
cough 10.4%
nasopharyngitis 10.4%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/12.5 mcg
upper respiratory tract infection 17.5%
nasopharyngitis 12.5%
cough 11.7%
NCT02175771 · Phase 3 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 18.1%
nasopharyngitis 13.4%
sinusitis 11.8%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/50 HFA
headache 15%
nasopharyngitis 9.2%
upper respiratory tract infection 6.4%
NCT00441441 · Phase 3 · registry result, not featured evidence
100 µg OD
cough 8.5% (placebo 5%)
headache 5.9% (placebo 1.7%)
rhinorrhoea 5.1% (placebo 1.7%)
NCT01563029 · Phase 2 · registry result, not featured evidence
50 µg OD
pharyngitis 5.8% (placebo 3.4%)
bronchitis 3.3% (placebo 0.8%)
nasopharyngitis 3.3% (placebo 3.4%)
NCT01563029 · Phase 2 · registry result, not featured evidence
25 µg OD
nasopharyngitis 7.6% (placebo 3.4%)
cough 5.9% (placebo 5%)
oropharyngeal pain 5.1% (placebo 0.8%)
NCT01563029 · Phase 2 · registry result, not featured evidence
12.5 OD
nasopharyngitis 8.8% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
25 OD
nasopharyngitis 7.9% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
6.25 OD
nasopharyngitis 7% (placebo 7%)
headache 5.3% (placebo 3.5%)
influenza 3.5% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
200 mcg
headache 4.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
100 mcg
headache 3.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
50 mcg
headache 4.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
400 mcg
headache 6.5% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 4.9% (placebo 2.9%)
nasopharyngitis 2.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence
50 mcg
nasopharyngitis 6.7% (placebo 4.8%)
upper respiratory tract infection 2.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
25 mcg
nasopharyngitis 4.8% (placebo 4.8%)
upper respiratory tract infection 1.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
12.5 mcg
upper respiratory tract infection 6.8% (placebo 2.9%)
nasopharyngitis 3.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

FEV1 Change 3 h 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcg
absolute change · L
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more results
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
ACQ-7 -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · score
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more result
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3

fluticasone propionate

Max Post-exercise FEV1 Fall 15.02% (n=70) vs 16.71% (n=69) FP @ 2wk100/25 µg QD
percent change · % of baseline
NCT02730351 · Phase 4 · registry result, not featured evidence
show 1 more result
11.9% (n=68) vs 14.05% (n=69) FP @ 2wk100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
FEV1 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Daily
absolute change · L
NCT02301975 · Phase 3 · registry result, not featured evidence
show 2 more results
0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
AM PEF Change L/Min 23.6 vs 9.8 Fluticasone Propionate L @ 52wk250/50 mcg BID
absolute change · L
NCT00452699 · Phase 4 · registry result, not featured evidence
Asthma Symptom Free 27.3 vs 28.6 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence
show 1 more result
37.1 vs 28.5 Fluticasone Propionate % of time @ 52wk250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
Severe Exacerbation Rate Annualized 1.87 vs 2.14 Fluticasone Propionate per year @ 52wk250/50 mcg BID
event rate · per year
NCT00452699 · Phase 4 · registry result, not featured evidence
show 1 more result
2.63 vs 2.73 FP DISKUS per year @ 52wk250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF 10.03 vs 2.24 placebo L @ 12wk200 mcg
absolute change · L
NCT01576718 · Phase 2 · registry result, not featured evidence
show 12 more results
10.29 vs 2.52 placebo L @ 12wk200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
16.3 vs 9.1 FP L @ 4wk100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
14.517 vs 3.591 placebo L @ 12wk100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
9.34 vs 2.24 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
9.39 vs 2.52 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
32 vs 12.3 placebo L @ 12wk50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
10.609 vs 3.591 placebo L @ 12wk50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
10.48 vs 2.24 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
10.85 vs 2.52 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
9.61 vs 2.24 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
10.4 vs 2.52 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
27.7 vs 14.6 FP DISKUS L @ 52wk250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
Asthma Symptom-Free 37.4 vs 28.9 FP DISKUS % of time @ 52wk250/50 mcg BID
percent change · % of time
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 26.9 vs 19.3 FP L @ 12wk50/100 mcg BD
absolute change · L
NCT00353873 · Phase 4 · registry result, not featured evidence
show 4 more results
27.55 vs 9.26 placebo L @ 12wk100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
29.58 vs 9.26 placebo L @ 12wk50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
21.01 vs 9.26 placebo L @ 12wk25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
30.99 vs 9.26 placebo L @ 12wk12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Morning PEF Change L/Min 27.7 vs 18.4 FP L/min @ 12wk50/100 mcg BD
absolute change · L/min
NCT00353873 · Phase 4 · registry result, not featured evidence
show 6 more results
13.7 vs 6.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
14.4 vs 7.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.9 vs 6.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
17 vs 7.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12 vs 6.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.3 vs 7.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Well-Controlled Asthma 43.3% (n=150) vs 40.1% (n=152) FP50/100 mcg BD
event count · % of participants
NCT00353873 · Phase 4 · registry result, not featured evidence · converted to % from 65 Participants as posted
FEV1 Max Fall -9.5% (n=113) vs -12.7% (n=104) FP @ 4wk100/50mcg BID
absolute value · percentage points
NCT00118716 · Phase 4 · registry result, not featured evidence
FEV1 AUC0-4h 0.7 vs 0.3 FP L @ 0wk100/50mcg BID
absolute change · L
NCT00118716 · Phase 4 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · fluticasone propionate's landscape